Skip to main content
Equibles
DARE logo

DARE · Dare Bioscience, Inc.

Track DARE — free

Use DARE with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about DARE

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.93 -0.44 (-32.12%) At close · Aug 14
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on our current analysis of the conditions described above, there is substantial doubt about our ability to continue as a going concern within the 12-month period from the issuance date of the accompanying condensed consolidated financial statements.”
View the 10-Q filed Aug 13, 2026
Market Cap
$14.22M
Shares
15.29M

Dare Bioscience, Inc. Earnings Call Transcripts

Every quarterly earnings call for Dare Bioscience, Inc. (DARE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $10.00M $413,998 '22 Q2 22-09-01 · $ −$7.02M '22 Q3 22-11-10 · $ −$8.04M '23 Q1 23-05-11 ▼100% $ −$8.76M '23 Q2 23-08-10 · $1.00M −$8.30M '23 Q3 23-11-09 · $1.81M −$5.06M '23 Q4 24-03-28 · $9,302 −$6.76M '24 Q1 24-05-14 · $22,438 $12.91M '24 Q2 24-08-12 ▼95.8% $41,691 −$4.70M '24 Q3 24-11-14 ▼103.5% $ −$5.51M '24 Q4 25-03-31 ▲173.3% $25,427 −$4.38M '25 Q1 25-05-13 ▼94.6% $2,262 −$3.56M '25 Q3 25-11-17 ▲499.6% $152,455 −$3.00M '26 Q1 26-05-14 LATEST · $187,546 −$2.98M '26 Q2 26-08-13
Earnings call
FY26 · Q2
2026-08-13
Daré Bioscience, Inc. Q2 2026 Conference Call
Confident tone Dare to Reclaim hormone therapy Financial performance Dare to Play Sildenafil Cream
Revenue
$187,546
Diluted EPS
$-0.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-14
Dare Bioscience, Inc. Q1 FY2026 Earnings Call
Positive tone DARE to PLAY commercial launch and provider uptake Ovaprene Phase 3 trial and contraceptive pipeline Flora Sync LF5 consumer health launch
Revenue
$152,455
▲ 499.6% YoY
Diluted EPS
$-0.21
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q3
2025-11-17
Dare Bioscience, Inc. Q3 FY2025 Earnings Call
Confident tone DARE to PLAY Sildenafil Cream Commercial Launch via 503B Women's Health Mission and Positioning Grant-Funded Clinical Pipeline
Revenue
$2,262
▼ 94.6% YoY
Diluted EPS
$-0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-14
Dare Bioscience, Inc. Q2 FY2025 Earnings Call
Confident tone DARE to PLAY Sildenafil cream commercial launch Ovaprene Phase III contraceptive trial Dual-path commercialization strategy
Diluted EPS
$-0.45
▼ 129.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Dare Bioscience, Inc. Q1 FY2025 Earnings Call
Confident tone Ovaprene Phase 3 / contraceptive Monthly hormone therapy (DARE-HRT1) Sildenafil Cream commercialization
Revenue
$25,427
▲ 173.3% YoY
Diluted EPS
$-0.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Dare Bioscience, Inc. Q4 FY2024 Earnings Call
Revenue
$*
▼ 103.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Dare Bioscience, Inc. Q3 FY2024 Earnings Call
Confident tone Sildenafil Cream 3.6% for female sexual arousal disorder DARE-PTB1 and DARE-VVA1 early-stage programs Ovaprene Phase III contraceptive study
Revenue
$41,691
▼ 95.8% YoY
Diluted EPS
$-0.55
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-12
Dare Bioscience, Inc. Q2 FY2024 Earnings Call
Positive tone Sildenafil Cream Phase 3 readiness Ovaprene contraceptive FDA interactions and regulatory risk
Revenue
$22,438
Diluted EPS
$1.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Dare Bioscience, Inc. Q1 FY2024 Earnings Call
Confident tone Sildenafil Cream Phase III for FSAD FDA regulatory interactions Ovaprene Phase III contraceptive
Revenue
$9,302
Diluted EPS
$-0.81
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-28
Dare Bioscience, Inc. Q4 FY2023 Earnings Call
Confident tone Ovaprene Phase 3 contraceptive XACIATO commercial launch with Organon Sildenafil Cream for FSAD
Revenue
$1.81M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Dare Bioscience, Inc. Q3 FY2023 Earnings Call
Revenue
$1.00M
Diluted EPS
$-1.09
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-10
Dare Bioscience, Inc. Q2 FY2023 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$-1.22
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-11
Dare Bioscience, Inc. Q1 FY2023 Earnings Call
Revenue
$
Diluted EPS
$-1.08
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-30
Dare Bioscience, Inc. Q4 FY2022 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-10
Dare Bioscience, Inc. Q3 FY2022 Earnings Call
Revenue
$
Diluted EPS
$-0.96
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-09-01
Dare Bioscience, Inc. Q2 FY2022 Earnings Call
Revenue
$10.00M
Diluted EPS
$0.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-12
Dare Bioscience, Inc. Q1 FY2022 Earnings Call
Diluted EPS
$-1.20
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-31
Dare Bioscience, Inc. Q4 FY2021 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-09-30
Dare Bioscience, Inc. Q3 FY2021 Earnings Call
Revenue
$
Diluted EPS
$-2.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-06-30
Dare Bioscience, Inc. Q2 FY2021 Earnings Call
Revenue
$
▼ 100% YoY
Diluted EPS
$-2.16
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-03-31
Dare Bioscience, Inc. Q1 FY2021 Earnings Call
Diluted EPS
$-1.92
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2020-12-31
Dare Bioscience, Inc. Q4 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-09-30
Dare Bioscience, Inc. Q3 FY2020 Earnings Call
Diluted EPS
$-2.88
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-06-30
Dare Bioscience, Inc. Q2 FY2020 Earnings Call
Revenue
$731,000
Diluted EPS
$-3.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-03-31
Dare Bioscience, Inc. Q1 FY2020 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–25 of 25 earnings calls
Key facts CIK 1401914 CUSIP 23666P200 13F (30d) 28 filings 28 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)